A. S. Igoshin
Research Subjects
A. S. Igoshin has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Yu. V. Karabach
Botkin City Clinical Hospital
2 shared publications - A. A. Komarova
Pirogov Russian National Research Medical University
1 shared publication - A. V. Levin
Botkin City Clinical Hospital
1 shared publication - A. V. Vardanyan
Russian Medical Academy of Continuous Professional Education
1 shared publication - A.E. Zavgorodniy
Botkin Moscow Multidisciplinary Scientific and Clinical Center
1 shared publication A.V. Kolkova
1 shared publication
Latest Publications
- Open Access
- 23 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6157
Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (pConclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.
- 23 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6157
Open AccessNon-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (pConclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (6) , 85-88
Otohematoma as manifestation of auricular arteriovenous malformation
Arteriovenous malformation (AVM, arteriovenous dysplasia) is one of the variants of congenital vascular defects formed as a result of a defect in the development of the arterial and venous systems during ontogenesis with the formation of direct messages between vessels of different diameters. In this regard, high-speed shunting of blood from the arterial part of the vascular system to the venous through fistulas of various calibers occurs. This disease is characterized by a variety of clinical manifestations. The auricle is the second most common site of extracranial AVM. Despite a large number of studies concerning etiological factors, diagnostic criteria and clinical aspects, differential diagnosis of auricular AVM in some cases is still difficult. The experience of differential diagnosis and sequence of actions in case of suspected auricular AVM is presented on the example of a clinical case.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (6) , 85-88
Otohematoma as manifestation of auricular arteriovenous malformation
Arteriovenous malformation (AVM, arteriovenous dysplasia) is one of the variants of congenital vascular defects formed as a result of a defect in the development of the arterial and venous systems during ontogenesis with the formation of direct messages between vessels of different diameters. In this regard, high-speed shunting of blood from the arterial part of the vascular system to the venous through fistulas of various calibers occurs. This disease is characterized by a variety of clinical manifestations. The auricle is the second most common site of extracranial AVM. Despite a large number of studies concerning etiological factors, diagnostic criteria and clinical aspects, differential diagnosis of auricular AVM in some cases is still difficult. The experience of differential diagnosis and sequence of actions in case of suspected auricular AVM is presented on the example of a clinical case.
- Open Access
- 16 January 2024
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 13 (2) , 38-43
Intimate sarcoma of the common femoral artery
Intimate sarcoma is a rare malignant tumor with a very poor prognosis. The incidence rate among all sarcomas is less than 1%. The primary localization of the tumor is most often the aorta and pulmonary artery. Other localizations account for about 10% of all observations. This tumor has an extremely nonspecific picture, is characterized by difficult diagnosis and poor prognosis. The main method of treatment is surgical – excision of the affected vessel and surrounding tissues with an interoperative histological examination, arterial reconstruction. About 140 cases of intimate sarcoma have been described in the literature. We present our own observation of intimate sarcoma. In the presented clinical case, the primary localization of the tumor was the common femoral artery. The patient was admitted with a clinical picture of a false femoral artery aneurysm, which was regarded as post-traumatic, without thrombosis or embolism of the distal bed and signs of limb ischemia. Repeated reconstructive surgical interventions were performed for a diagnosed false aneurysm. The intraoperative picture did not indicate any oncological process. After discharge, within six months there were two repeated requests for emergency indications in connection with erosive bleeding in the area of surgery. There were no signs of paraprosthetic infection. The oncological process was suspected with the appearance and growth of a voluminous formation of the inguinal region, which became the reason for performing a histological examination. The final diagnosis was made in the late stage of the disease, when radical surgical treatment was not feasible. The ongoing chemotherapeutic treatment did not have a significant effect, which led to an unfavorable outcome.
- 16 January 2024
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 13 (2) , 38-43
Open AccessIntimate sarcoma of the common femoral artery
Intimate sarcoma is a rare malignant tumor with a very poor prognosis. The incidence rate among all sarcomas is less than 1%. The primary localization of the tumor is most often the aorta and pulmonary artery. Other localizations account for about 10% of all observations. This tumor has an extremely nonspecific picture, is characterized by difficult diagnosis and poor prognosis. The main method of treatment is surgical – excision of the affected vessel and surrounding tissues with an interoperative histological examination, arterial reconstruction. About 140 cases of intimate sarcoma have been described in the literature. We present our own observation of intimate sarcoma. In the presented clinical case, the primary localization of the tumor was the common femoral artery. The patient was admitted with a clinical picture of a false femoral artery aneurysm, which was regarded as post-traumatic, without thrombosis or embolism of the distal bed and signs of limb ischemia. Repeated reconstructive surgical interventions were performed for a diagnosed false aneurysm. The intraoperative picture did not indicate any oncological process. After discharge, within six months there were two repeated requests for emergency indications in connection with erosive bleeding in the area of surgery. There were no signs of paraprosthetic infection. The oncological process was suspected with the appearance and growth of a voluminous formation of the inguinal region, which became the reason for performing a histological examination. The final diagnosis was made in the late stage of the disease, when radical surgical treatment was not feasible. The ongoing chemotherapeutic treatment did not have a significant effect, which led to an unfavorable outcome.
- 1 January 2023
- Published by Geotar-Media Publishing Group in Angiology and vascular surgery
- Vol. 29 (2)
Successful treatment of a patient with ruptured abdominal aortic aneurysm, COVID-19, and prosthesis infection (case report)
Инфицирование синтетического протеза после протезирования по поводу разрыва аневризмы аорты у больного с COVID-19 (клиническое наблюдение)
- 1 January 2023
- Published by Geotar-Media Publishing Group in Angiology and vascular surgery
- Vol. 29 (2)
Successful treatment of a patient with ruptured abdominal aortic aneurysm, COVID-19, and prosthesis infection (case report)
Инфицирование синтетического протеза после протезирования по поводу разрыва аневризмы аорты у больного с COVID-19 (клиническое наблюдение)